PharmaCyte Biotech, Inc. Earnings Per Share Diluted

• PharmaCyte Biotech, Inc. showed an increase of +277.2% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2021: $0.64 (loss) per share | Q4 2021: $0.06 (loss) per share | Q1 2022: $0.04 (loss) per share | Q3 2022: $0.07 (loss) per share | Q4 2022: $0.09 (loss) per share | Q1 2023: $0.04 (loss) per share | Q3 2023: $0.54 (loss) per share | Q4 2023: $0.26 (loss) per share | Q1 2024: $0.65 (loss) per share | Q3 2024: $1.90 per share | Q4 2024: $0.39 (loss) per share | Q1 2025: $0.44 (loss) per share | Q3 2025: $1.23 (loss) per share | Q4 2025: $1.24 (loss) per share | Q1 2026: $0.17 (loss) per share.
• Over the full 5 years of available data (2021 to 2025), PharmaCyte Biotech, Inc.'s Earnings Per Share Diluted has grown by 230.2%.
• Historical annual values: Fiscal year 2025: $3.19 per share | Fiscal year 2024: $1.80 (loss) per share | Fiscal year 2023: $0.22 (loss) per share | Fiscal year 2022: $0.27 (loss) per share | Fiscal year 2021: $2.45 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026